Abstract
Animal models for opportunistic infections were developed by using mice immunosuppressed by 5-FU. These mice were susceptible to various microorganisms, while normal mice had greater tolerance to such microbial infections. In these models, thymosin alpha 1 was found to protect mice against lethal infections with Candida albicans, Listeria monocytogenes, Pseudomonas aeruginosa, and Serratia marcescens when it was administered during 5-FU treatment prior to the infections. Thymosin alpha 1 was effective in some infections at 0.4-400 micrograms/kg/day IP, about 1/100 of the dose required for thymosin fraction 5. Activity was also demonstrated against L-monocytogenes and Ps. aeruginosa by counting the viable bacteria in the liver after infection. The protective activity against Candida, elimination of which macrophages were essential, was abrogated by anti-thymocyte serum and/or carrageenan, indicating that thymosin alpha 1 serves to maintain the functions of macrophages by reducing the damage to T cells by 5-FU. On the other hand, the activity against Pseudomonas infection was not affected by anti-thymocyte serum or carrageenan. It is probable that thymosin alpha 1 also exerts its effect on neutrophils without participation of T c...Continue Reading
References
Nov 1, 1979·Journal of General Microbiology·K TatsukawaK Nomoto
Feb 28, 1975·Annals of the New York Academy of Sciences·J A HooperA L Goldstein
Feb 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·A L GoldsteinJ Meienhofer
Mar 1, 1978·The Journal of Experimental Medicine·N H PazmiñoA L Goldstein
May 1, 1977·The American Journal of Medicine·C SingerD Armstrong
Jan 9, 1975·The New England Journal of Medicine·D W WaraA J Ammann
Jun 1, 1975·Cancer Treatment Reviews·G P Bodey
Jun 1, 1972·Cellular Immunology·R J HartzmanK W Sell
Oct 1, 1966·Proceedings of the National Academy of Sciences of the United States of America·R H Levey, P B Medawar
Jan 1, 1981·Journal of Interferon Research·K Y HuangA L Goldstein
Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·I GoldschneiderA L Goldstein
Feb 1, 1958·Proceedings of the Society for Experimental Biology and Medicine·C HEIDELBERGERE GRUNBERG
Citations
Feb 10, 1988·Journal of Immunological Methods·P P YialourisA A Haritos
Jan 1, 1985·International Journal of Immunopharmacology·Y OhtaY Yagi
Jan 1, 1986·International Journal of Immunopharmacology·Y OhtaY Yagi
Jan 1, 1989·International Journal of Immunopharmacology·C FavalliE Garaci
Sep 1, 1994·International Journal of Immunopharmacology·J W Hadden
Dec 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·J CaldarellaB L Horecker
Feb 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·A A HaritosB L Horecker
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·A A HaritosB L Horecker
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·W H Eschenfeldt, S L Berger
Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·T KomiyamaB L Horecker
Oct 12, 2012·Annals of the New York Academy of Sciences·Annalucia SerafinoEnrico Garaci
Jul 1, 1985·Cellular Immunology·V J TomazicJ V Ordonez
Nov 1, 1989·Clinical Immunology and Immunopathology·P G VlachoyiannopoulosO Tsolas
Aug 1, 2018·Expert Opinion on Biological Therapy·Na YangWeiqin Li
Apr 27, 2001·Immunopharmacology and Immunotoxicology·H OhmoriN Kanayama
Sep 27, 2019·Frontiers in Oncology·Claudio CostantiniLuigina Romani